SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1782-1789. Prepublished online as a Blood First Edition Paper on October 24, 2006; DOI 10.1182/blood-2006-06-031682. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-06-031682v1 109/4/1782    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oehler, V. G. Articles by Radich, J. P. Search for Related Content PubMed PubMed Citation Articles by Oehler, V. G. Articles by Radich, J. P. Related Collections Neoplasia Transplantation Oncogenes and Tumor Suppressors Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Vivian G. Oehler1, Ted Gooley1, David S. Snyder2, Laura Johnston3, Allen Lin2, Carrie C. Cummings1, Su Chu2, Ravi Bhatia2, Stephen J. Forman2, Robert S. Negrin3, Frederick R. Appelbaum1, and Jerald P. Radich1 1 Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA; 2 Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA; 3 Division of Bone Marrow Transplantation, Stanford University, CA The impact of imatinib mesylate (IM) treatment for chronic myeloid leukemia (CML) on subsequent allogeneic transplantation is uncertain. To better understand this relationship, we retrospectively compared 145 patients with CML receiving IM for a minimum of 3 months before allogeneic hematopoietic cell transplantation (HCT) to 231 patients with CML who did not. IM treatment was associated with no increase in early hepatotoxicity or engraftment delay after HCT compared with the historical cohort. In addition, there was no statistically significant difference in the IM-treated cohort compared with the historical cohort with regard to overall survival, disease-free survival, relapse, and nonrelapse mortality. For chronic-phase (CP) patients, IM response prior to HCT was associated with post-HCT outcome. Patients who underwent transplantation in CP with a suboptimal response or a loss of response on IM had a statistically significant higher hazard of mortality when compared with CP patients who achieved a complete cytogenetic response (CCR) or major cytogenetic response (MCR) on IM (HR = 5.31, 95% confidence interval [CI] 1.13-25.05, P = .03). These data indicate that pre-HCT IM is not associated with increased transplant-related morbidity (TRM) or poorer outcomes. However, patients with a suboptimal or loss of IM response before HCT do worse, suggesting a more aggressive disease course for these patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Xiao-Jun, X. Lan-Ping, L. Kai-Yan, L. Dai-Hong, W. Yu, C. Huan, C. Yu-Hong, H. Wei, W. Jing-Zhi, C. Yao, et al. Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable with Unrelated Donor Transplantation for Patients with Hematologic Malignancies Clin. Cancer Res., July 15, 2009; 15(14): 4777 - 4783. [Abstract] [Full Text] [PDF] S. J. Lee, M. Kukreja, T. Wang, S. A. Giralt, J. Szer, M. Arora, A. E. Woolfrey, F. Cervantes, R. E. Champlin, R. P. Gale, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia Blood, October 15, 2008; 112(8): 3500 - 3507. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] J. P. Radich The Biology of CML Blast Crisis Hematology, January 1, 2007; 2007(1): 384 - 391. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020